Why the study?
Does pazopanib show clinical activity in patients with advanced vascular sarcomas?
Does pazopanib show clinical activity in patients with advanced vascular sarcomas?
Pazopanib demonstrates promising clinical activity in advanced vascular sarcomas, warranting further evaluation.
This is the authors' abstract. We don't add key points for this paper.
The activity of pazopanib in AS is comparable to its reported activity in other STS subtypes. In this study, the activity of pazopanib was similar in cutaneous/non-cutaneous and in radiation/non-radiation-associated AS. In addition, pazopanib showed promising activity in HE and IS, worthy of further evaluation.
Answers are grounded in this paper and cite their sources.
May support pazopanib in advanced vascular sarcomas; leaves open randomized confirmation before practice change.
No takes yet. Share an insight, caveat, or question.
Kollár et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: